I wrote a long reply to the SEC about GNBT's S-1

I wrote a long reply to the SEC about GNBT's S-1 and will follow up with a call on Monday. Gave a little Generex history lesson, need for funding for the important CV-19 and breast cancer work, uplisting etc. I was polite but also clear how this S-1 affects not only Generex but potentially my families financial future.